<List><item><source>MED</source><extId>29123263</extId><pmcid>PMC5729466</pmcid><annotations><annotation><prefix>X plus bevacizumab (</prefix><exact>NCT01067053</exact><postfix>) (Feliu et al, 2014</postfix><tags><tag><name>NCT01067053</name><uri>http://identifiers.org/clinicaltrials/NCT01067053</uri></tag></tags><id>http://europepmc.org/articles/PMC5729466#europepmc-4eb092a777833d41794db9141cdd0b21</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>6 plus panitumumab (</prefix><exact>NCT01288339</exact><postfix>) (Maurel et al, 201</postfix><tags><tag><name>NCT01288339</name><uri>http://identifiers.org/clinicaltrials/NCT01288339</uri></tag></tags><id>http://europepmc.org/articles/PMC5729466#europepmc-7340440bf70e3165e5da1bd1d1c8b83c</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>biweekly cetuximab (</prefix><exact>NCT01276379</exact><postfix>) (Alonso et al, 201</postfix><tags><tag><name>NCT01276379</name><uri>http://identifiers.org/clinicaltrials/NCT01276379</uri></tag></tags><id>http://europepmc.org/articles/PMC5729466#europepmc-0c399f5b7ab2fbe05fea590ee3b1c834</id><type>Accession Numbers</type><section>Methods (http://purl.org/orb/Methods)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>